## Dudley Group NHS Foundation Trust: Equality Impact Assessment

## Step 2 - Screening Tool

Please complete the following when screening your policy or service for potential impact on equality groups.

1. Name of lead	R. Kahlon Principal Pharmacist – Preparative Services
Contact number & email	Ext: 3320
	Ruckie.Kahlon@dgh.nhs.uk
Directorate or Department and Team	Operations Directorate
2. Name of service or policy	Intrathecal Chemotherapy Procedure
Is this a new or existing piece of work?	Existing policy - updated
<b>3. Target audience</b> e.g. patients and public; NHS staff; professional health organisations; voluntary organisation; internal staff	All hospital and community staff handling systemic anticancer and related monoclonal antibodies at the DG NHS FT. Only staff trained, deemed competent by their assessors and named on the intrathecal chemotherapy register may undertake any process involving intrathecal chemotherapy administration.
4. What are the aims of the service/ policy? i.e. what does the policy or service hope to achieve?	This policy aims to minimise the risks by promoting safe prescribing, safe handling and administration of intrathecal chemotherapy within the Trust.
5. Does any part of this service or policy have the potential to have an adverse impact based on a person's age, disability, ethnic origin, gender, religion/belief or sexual orientation?	No. This is an operational policy outlining procedures to prescribe, handle and administer intrathecal chemotherapy. The patients will undergo informed consent of their intended therapy and staff will undergo competency based

If No, please provide brief reasons.	training to achieve the aims of this policy
6. Are there any factors that could lead to different outcomes or satisfaction levels based on people's age, disability, ethnic origin, gender, religion/belief or sexual orientation?	No. Staff will undergo competency based training to ensure desirable outcome of their role associated to intrathecal chemotherapy prescribing / preparation / administration.
If No, please provide brief reasons.	Patients will undergo informed consent outlining the potential side effects of their treatment.

Name of person completing this screening: R. Kahlon

Job Title: Principal Pharmacist – Preparative Services

Date sent to Head of Service, Matron or Head of department: 01/03/13

Date sent to Head of Communications, Trust HQ:01/03/13